PSA assay and reagent therefor

Patent metadata

Field	Value
Publication number	US-10119963-B2
Application number	US-201514865728-A
Country	US
Kind code	B2
Filing date	Sep 25, 2015
Priority date	Mar 28, 2011
Publication date	Nov 6, 2018
Grant date	Nov 6, 2018

Abstract

Provided is a method for the simple and highly accurate assay of PSA by a one-step reaction that does not use carriers having different average grain sizes. Also provided is a reagent therefor. The PSA assay method comprises sensitizing insoluble carriers having the same average grain size within a range of greater than 0.20 μm but 0.40 μm or less using two types of anti-PSA monoclonal antibodies having different epitopes that are anti-PSA monoclonal antibodies that will react with both free PSA and PSA-ACT, which is a complex of free PSA and α1-antichymotrypsin, and bringing the carriers into contact with a sample in the presence of an aggregation promoter.

First claim

The invention claimed is:

1. A prostate specific antigen (“PSA”) assay comprising:
providing a mixture of insoluble carriers with two kinds of anti-PSA monoclonal antibodies respectively immobilized thereon, and
bringing said mixture into contact with a sample in the presence of an agglutination accelerator, and thereby, reacting two kinds of anti-PSA monoclonal antibodies at one time, wherein said agglutination accelerator excludes PEG6000,
wherein
the two kinds of anti-PSA monoclonal antibodies can react with both free PSA and complex of free PSA and α1-antichymotrypsin (PSA-ACT) by recognizing different epitopes,
each of the two kinds of anti-PSA monoclonal antibodies has a ratio (fKd/cKd) of a dissociation constant (fKd) for free PSA to a dissociation constant (cKd) for complex of free PSA and α1-antichymotrypsin (PSA-ACT) of more than 0.1 and equal to or less than 2.0 in the absence of said agglutination accelerator,
each of the two kinds of anti-PSA monoclonal antibodies has a dissociation constant (fKd) for free PSA of 10 nM or less,
the insoluble carriers have an identical average particle size that is more than 0.20 μm and equal to or less than 0.40 μm, and
the concentration of the agglutination accelerator has been set so that an equimolar response to free PSA and complex of free PSA and α1-antichymotrypsin (PSA-ACT) is obtained, said equimolar response obtained when c/f ratio is 90 to 115%, said c/f ratio being the ratio (PSA-ACT/fPSA) of the reactivity with PSA-ACT to the reactivity with fPSA.

2. The PSA assay according to claim 1 , wherein the agglutination accelerator is one or more agglutination accelerators selected from a polysaccharide, polyvinylpyrrolidone, polyvinyl chloride, a poly-γ-glutamate, and poly(2-methacryloyloxyethylphosphorylcholine).

3. The PSA assay according to claim 1 , wherein the insoluble carriers are of one or more type selected from particles comprising materials derived from latex particles of synthetic polymers, silica, alumina, carbon blacks, metal compounds, metals, ceramics, and/or magnetic substances.

4. The PSA assay according to claim 2 , wherein the polysaccharide is one or more polysaccharides selected from dextran, pullulan, and alkylated polysaccharides.

5. The PSA assay according to claim 3 , wherein the synthetic polymer is one or more synthetic polymers selected from polystyrene, a styrene-sulfonic acid copolymer, a styrene-methacrylic acid copolymer, an acrylonitrile-butadiene-styrene copolymer, a vinyl chloride-acrylate copolymer, and a vinyl acetate-acrylate copolymer.

6. The PSA assay according to claim 4 , wherein the polysaccharide is methyl cellulose and/or ethyl cellulose.

7. A prostate specific antigen (“PSA”) assay comprising:
contacting a sample with a Reagent A to form a mixture, said Reagent A including a mixture of insoluble carriers with two kinds of anti-PSA monoclonal antibodies respectively immobilized thereon, and thereby, reacting two kinds of anti-PSA monoclonal antibodies at one time, and
wherein
the two kinds of anti-PSA monoclonal antibodies can react with both free PSA and complex of free PSA and α1-antichymotrypsin (PSA-ACT) and recognize different epitopes,
each of the two kinds of anti-PSA monoclonal antibodies has a ratio (fKd/cKd) of a dissociation constant (fKd) for free PSA to a dissociation constant (cKd) for complex of free PSA and α1-antichymotrypsin (PSA-ACT) of more than 0.1 and equal to or less than 2.0 in the absence of said agglutination accelerator,
each of the two kinds of anti-PSA monoclonal antibodies has a dissociation constant (fKd) for free PSA of 10 nM or less, and
the insoluble carriers have an identical average particle size that is more than 0.20 μm and equal to or less than 0.40 μm; and
reacting the mixture of the sample and Reagent A with a Reagent B, said Reagent B including one or more agglutination accelerators selected from polyethylene glycol, a polysaccharide, polyvinylpyrrolidone, polyvinyl chloride, a poly-γ-glutamate, and poly(2-methacryloyloxyethylphosphorylcholine), wherein said agglutination accelerator excludes PEG6000,
wherein the concentration of the agglutination accelerator has been set so that an equimolar response to free PSA and complex of free PSA and α1-antichymotrypsin (PSA-ACT) is obtained, said equimolar response obtained when c/f ratio is 90 to 115%, said c/f ratio being the ratio (PSA-ACT/fPSA) of the reactivity with PSA-ACT to the reactivity with fPSA.

8. The PSA assay according to claim 7 , wherein the insoluble carriers are of one or more type selected from particles comprising materials derived from latex particles of synthetic polymers, silica, alumina, carbon blacks, metal compounds, metals, ceramics, and/or magnetic substances.

9. The PSA assay according to claim 8 , wherein the synthetic polymer is one or more synthetic polymers selected from polystyrene, a styrene-sulfonic acid copolymer, a styrene-methacrylic acid copolymer, an acrylonitrile-butadiene-styrene copolymer, a vinyl chloride-acrylate copolymer, and a vinyl acetate-acrylate copolymer.

10. The PSA assay according to claim 7 , wherein the polysaccharide is one or more polysaccharides selected from dextran, pullulan, and alkylated polysaccharides.

11. The PSA assay according to claim 10 , wherein the alkylated polysaccharides are methyl cellulose and/or ethyl cellulose.

Assignees

• Sekisui Medical Co Ltd

Inventors

• Takahashi Yuki
• Shimizu Tomo
• Nakamura Yasushi
• Nakayama Shinya
• Kitahara Shinichiro

Classifications

• G01N33/57555 Primary

  of the prostate · CPC title

• G01N33/575 Primary

  for cancer · CPC title

• G01N2333/96433

  Serine endopeptidases (3.4.21) · CPC title

• G01N33/573 Primary

  for enzymes or isoenzymes · CPC title

• G01N33/57434

  Physics · mapped topic